Johnson & Johnson Reports registry Data for Iptacopan in HIV

Johnson & Johnson today announced registry results for iptacopan in patients with HIV. The study demonstrated that iptacopan demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of HIV and support the continued development of iptacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.